Mechanistically, MEF2A induced by RBM15/IGF2BP1-mediated m6A modification can transcriptionally upregulate PD-L1 to stabilize SOX12 mRNA, thereby causing suppression of cetuximab sensitivity in CRC. The gene discussed is IGF2BP1; the disease is colorectal carcinoma.